ABSTRACT
OBJECTIVE: To explore the expression of renin-angiotensin system component (ACE-AngII-AT1/AT2 & ACE2-Ang-(1-7)-Mas) in endometrium of polycystic ovary syndrome (PCOS) patients and normal controls. METHODS: Thirty cases of normal endometrium in proliferative and secretory phases respectively were selected for the protein levels of AngII, AT1, AT2, ACE2, Ang-(1-7) and Mas through immunohistochemistry. And the specimens of proliferative endometrium from 15 PCOS patients and 15 normal controls respectively were prepared for the expressions of AT1, AT2, ACE2 and Mas mRNA through relative quantitative -polymerase chain reaction (RQ-PCR). The histological phases of endometria were confirmed by hematoxylin & eosin staining under microscope. RESULTS: The expressions of AngII, AT1R, AT2R, ACE2, Ang-(1-7) and Mas showed periodical changes in endometrium throughout normal menstrual cycles and shared a similar trend. The expression was more pronounced in epithelial cells than that in stromal cells while it was also more dramatic in secretory phase than proliferative phase; The mRNA expressions of AT1, AT2, ACE2 and MAS were higher in PCOS endometrium than those in normal controls. Statistically significant differences existed between two groups (P < 0.01). CONCLUSIONS: There is local existence of RAS in endometrium; Increased expressions of AT1 mRNA, AT2 mRNA, ACE2 mRNA and Mas mRNA in endometrium of PCOS may influence endometrial development and play a role in the pathological process of PCOS.
Subject(s)
Angiotensin I/metabolism , Endometrium/metabolism , Peptide Fragments/metabolism , Peptidyl-Dipeptidase A/metabolism , Polycystic Ovary Syndrome/metabolism , Proto-Oncogene Proteins/metabolism , Receptors, G-Protein-Coupled/metabolism , Renin-Angiotensin System , Adult , Angiotensin II/metabolism , Angiotensin-Converting Enzyme 2 , Case-Control Studies , Female , Humans , Proto-Oncogene Mas , Receptors, Angiotensin/metabolism , Young AdultABSTRACT
OBJECTIVE: To assess the significance of intraluminal ultrasound in the diagnosis of developmental status and treatment effect in normal and idiopathic precocious puberty (ICPP) girls. METHODS: Endorectal ultrasonography was used to measure the parameters of uterine length, width, thickness, cervix length, ovarian volume and maximum follicular length in normal girls and compare their differences between pre- and post-treatment by gonadotropin-releasing hormone analogues (GnRHa) in idiopathic precocious puberty girls. RESULTS: The ultrasonic parameters of uterus and ovary in normal girls significantly increased in average 9-year-old girls (1.87 ± 0.58) ml of uterine volume in 9-year-old group vs (1.03 ± 0.24) ml in 7-year-old group; ovarian volume (3.01 ± 2.73) ml of uterine volume in 9-year-old group vs 0.98 ± 0.36 ml in 7-year-old group. They were much greater in ICPP girls and decreased significantly at post-treatment, (1.16 ± 0.19) ml of uterus volume pre-treatment vs (1.02 ± 0.15) ml post-treatment; (2.11 ± 0.48) ml of ovarian volume pre-treatment, (1.72 ± 0.55) ml post-treatment; (1.36 ± 0.25) cm of the biggest follicular diameter pre-treatment, (1.16 ± 0.36) cm post-treatment. CONCLUSION: Endosonography is an important tool of evaluating the development status and treatment effect in normal and ICPP girls.